187 related articles for article (PubMed ID: 34094032)
1. Pathogenic role of the SP/ NK1R system in GBM cells through inhibiting the thioredoxin system.
Ghahremani F; Sabbaghzadeh R; Ebrahimi S; Javid H; Ghahremani J; Hashemy SI
Iran J Basic Med Sci; 2021 Apr; 24(4):499-505. PubMed ID: 34094032
[TBL] [Abstract][Full Text] [Related]
2. The SP/NK1R System-Mediated ROS Generation in GBM Cells through Inhibiting Glutaredoxin Protein.
Mehrabani N; Vaezi Kakhki MR; Javid H; Ebrahimi S; Hashemy SI
Neurol Res Int; 2021; 2021():9966000. PubMed ID: 34917417
[TBL] [Abstract][Full Text] [Related]
3. The effect of SP/NK1R on expression and activity of glutaredoxin and thioredoxin proteins in prostate cancer cells.
Zarei Shandiz S; Assaran Darban R; Javid H; Ghahremanloo A; Hashemy SI
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; ():. PubMed ID: 38334824
[TBL] [Abstract][Full Text] [Related]
4. The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses.
Jafarinezhad S; Assaran Darban R; Javid H; Hashemy SI
Cell Biochem Biophys; 2023 Dec; 81(4):787-794. PubMed ID: 37740877
[TBL] [Abstract][Full Text] [Related]
5. The Therapeutic Potential of Aprepitant in Glioblastoma Cancer Cells through Redox Modification.
Rezaei S; Assaran Darban R; Javid H; Hashemy SI
Biomed Res Int; 2022; 2022():8540403. PubMed ID: 35281606
[TBL] [Abstract][Full Text] [Related]
6. The Effect of SP/NK1R on the Expression and Activity of Catalase and Superoxide Dismutase in Glioblastoma Cancer Cells.
Korfi F; Javid H; Assaran Darban R; Hashemy SI
Biochem Res Int; 2021; 2021():6620708. PubMed ID: 33976938
[TBL] [Abstract][Full Text] [Related]
7. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
8. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.
Ebrahimi S; Mirzavi F; Aghaee-Bakhtiari SH; Hashemy SI
Biochim Biophys Acta Mol Cell Res; 2022 May; 1869(5):119221. PubMed ID: 35134443
[TBL] [Abstract][Full Text] [Related]
9. The effect of substance P and its specific antagonist (aprepitant) on the expression of MMP-2, MMP-9, VEGF, and VEGFR in ovarian cancer cells.
Momen Razmgah M; Ghahremanloo A; Javid H; AlAlikhan A; Afshari AR; Hashemy SI
Mol Biol Rep; 2022 Oct; 49(10):9307-9314. PubMed ID: 35960409
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Blocking Neurokinin-1 Receptor by Aprepitant on the Inflammatory and Apoptosis Pathways in Human Ovarian Cancer Cells.
AlAlikhan A; Ghahremanloo A; Javid H; Ebrahimi S; Hashemy SI
Cell Biochem Biophys; 2022 Dec; 80(4):819-827. PubMed ID: 36197642
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the Role of Neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K/Akt/NF-
Ghahremanloo A; Javid H; Afshari AR; Hashemy SI
Biomed Res Int; 2021; 2021():1383878. PubMed ID: 34395609
[TBL] [Abstract][Full Text] [Related]
12. The redox modulatory effects of SP/NK1R system: Implications for oxidative stress-associated disorders.
Ebrahimi S; Alalikhan A; Aghaee-Bakhtiari SH; Hashemy SI
Life Sci; 2022 May; 296():120448. PubMed ID: 35247438
[TBL] [Abstract][Full Text] [Related]
13. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
14. Thioredoxin Reductase Inhibitors as Potential Antitumors: Mercury Compounds Efficacy in Glioma Cells.
Pires V; Bramatti I; Aschner M; Branco V; Carvalho C
Front Mol Biosci; 2022; 9():889971. PubMed ID: 35813817
[TBL] [Abstract][Full Text] [Related]
15. Expression of different neurokinin-1 receptor (NK1R) isoforms in glioblastoma multiforme: potential implications for targeted therapy.
Cordier D; Gerber A; Kluba C; Bauman A; Hutter G; Mindt TL; Mariani L
Cancer Biother Radiopharm; 2014 Jun; 29(5):221-6. PubMed ID: 24552486
[TBL] [Abstract][Full Text] [Related]
16. A thioredoxin reductase and/or thioredoxin system-based mechanism for antioxidant effects of ambroxol.
Huang J; Xu J; Tian L; Zhong L
Biochimie; 2014 Feb; 97():92-103. PubMed ID: 24103200
[TBL] [Abstract][Full Text] [Related]
17. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.
Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C
Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954
[TBL] [Abstract][Full Text] [Related]
18. The thioredoxin antioxidant system.
Lu J; Holmgren A
Free Radic Biol Med; 2014 Jan; 66():75-87. PubMed ID: 23899494
[TBL] [Abstract][Full Text] [Related]
19. The in vitro anti-cancer synergy of neurokinin-1 receptor antagonist, aprepitant, and 5-aminolevulinic acid in glioblastoma.
Ebrahimi S; Mirzavi F; Hashemy SI; Khaleghi Ghadiri M; Stummer W; Gorji A
Biofactors; 2023; 49(4):900-911. PubMed ID: 37092793
[TBL] [Abstract][Full Text] [Related]
20. Tachykinin Receptor-Selectivity of the Potential Glioblastoma-Targeted Therapy, DOTA-[Thi
Suthiram J; Pieters A; Mohamed Moosa Z; Zeevaart JR; Sathekge MM; Ebenhan T; Anderson RC; Newton CL
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
